Rhodes Jason P 4
4 · Dyne Therapeutics, Inc. · Filed Jun 30, 2026
Research Summary
AI-generated summary of this filing
Dyne Therapeutics (DYN) Director Jason P. Rhodes Sells Shares
What Happened
- Jason P. Rhodes, a director of Dyne Therapeutics (DYN), disposed of a total of 504,695 shares in open-market sales on June 26 and June 29, 2026, generating aggregate proceeds of approximately $10.7 million. The June 26 blocks reported a weighted-average price of $21.28; the June 29 blocks reported a weighted-average price of $21.14. These transactions are sales (code S) and represent liquidity rather than a purchase-based bullish signal.
Key Details
- Transaction dates and amounts:
- 2026-06-26: 162,954 shares @ $21.28 = $3,467,661 (F2)
- 2026-06-26: 81,903 shares @ $21.28 = $1,742,896 (F2)
- 2026-06-26: 64,411 shares @ $21.28 = $1,370,666 (F2)
- 2026-06-29: 102,969 shares @ $21.14 = $2,176,765 (F6)
- 2026-06-29: 51,756 shares @ $21.14 = $1,094,122 (F6)
- 2026-06-29: 40,702 shares @ $21.14 = $860,440 (F6)
- Total: 504,695 shares; total proceeds ≈ $10,712,550.
- Filing: Form 4 filed June 30, 2026, reporting transactions on June 26 and June 29, 2026 (appears filed within the typical 2-business-day window).
- Plan and price details: Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 19, 2026 (F1). Reported prices are weighted averages; individual sale prices ranged (per footnotes) from $21.00 up to $21.61 and up to $21.3247 for the separate groups (F2, F6).
- Ownership/beneficial interest: Several blocks were held by Atlas Venture partnership entities (Atlas Venture Fund XI, Atlas Venture Opportunity Fund I & II, AVA partnerships). Rhodes disclaims Section 16 beneficial ownership of those fund-held securities except to the extent of any pecuniary interest (F3–F5, F7).
- Shares owned after transaction: Not specified in the provided filing excerpt.
Context
- These were planned, pre-arranged sales (10b5-1), a common mechanism for insiders to sell shares without running afoul of insider-trading rules. Because the shares were held via venture funds and the reporting person disclaims beneficial ownership for many blocks, these transactions reflect institutional/fund dispositions more than a personal purchase decision. Sales do not by themselves indicate company fundamentals; retail investors often weigh insider purchases more heavily as signals.
Insider Transaction Report
Form 4
Rhodes Jason P
Director
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-06-26$21.28/sh−162,954$3,467,661→ 4,579,456 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F4]2026-06-26$21.28/sh−81,903$1,742,896→ 1,396,475 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F5]2026-06-26$21.28/sh−64,411$1,370,666→ 1,016,633 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F3]2026-06-29$21.14/sh−102,969$2,176,765→ 4,476,487 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F4]2026-06-29$21.14/sh−51,756$1,094,122→ 1,344,719 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F5]2026-06-29$21.14/sh−40,702$860,440→ 975,931 total(indirect: See footnote)
Holdings
- 7,962(indirect: See footnote)
Common Stock
[F7]
Footnotes (7)
- [F1]Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
- [F2]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6).
- [F3]The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.
- [F4]The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.
- [F5]The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
- [F6]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive.
- [F7]The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any.
Signature
/s/ Ommer Chohan, Attorney-in-Fact|2026-06-30